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Background. CCR5 and CCR2 gene polymorphisms (SNPs) have been associated with protection against HIV transmission in
adults and with delayed progression to AIDS. The CCR5 D32 deletion and SNP -2459G are associated with reduced expression of
the CCR5 protein. Methodology/Principal Findings. We investigated the association between infant CCR2/CCR5 diplotype
and HIV mother to child transmission (MTCT) in Malawi. Blood samples from infants (n=552) of HIV positive women who
received nevirapine were genotyped using a post-PCR multiplex ligase detection reaction and haplotypes were identified based
on 8 CCR2/CCR5 SNPs and the open reading frame 32 base pair deletion. Following verification of Hardy-Weinberg equilibrium,
log linear regression was performed to examine the association between mutations and MTCT. Overall, protection against MTCT
was weakly associated with twoCCR5 SNPs, -2459G(Risk ratio [RR], 0.78; confidence interval [CI], 0.54–1.12), and the linked CCR5
-2135T (RR, 0.78; CI, 0.54–1.13). No child carried the CCR5 D32 SNP. Maternal Viral Load (MVL) was found to be an effect measure
modifier. Among mothers with low MVL, statistically significant protection against MTCT was observed for -2459G (RR, 0.50; CI,
0.27–0.91), and -2135T (RR, 0.51; CI, 0.28–0.92). Statistically significant protection was not found at high MVL. Conclusions/
Significance. Results from this study suggest that CCR5 SNPs -2459G and -2135T associated with reduced receptor expression
protect against MTCT of HIV at low MVLs, whereas high MVLs may over-ride differences in coreceptor availability.
Citation: Pedersen BR, Kamwendo D, Blood M, Mwapasa V, Molyneux M, et al (2007) CCR5 Haplotypes and Mother-to-Child HIV Transmission in
Malawi. PLoS ONE 2(9): e838. doi:10.1371/journal.pone.0000838
INTRODUCTION
An estimated 600,000 children per year are infected with HIV-1,
the majority of them by mother-to-child transmission (MTCT) [1].
Most of these children live in sub-Saharan Africa, where access to
methods of preventing MTCT is still rare. MTCT can occur in
utero, during labor and delivery, or through breastfeeding [2,3].
There is evidence in children and adults that naturally occurring
variations in HIV-1/chemokine receptors influence the risk of
HIV-1 transmission and rate of HIV/AIDS disease progression.
Genetic variations in chemokine receptor 5 (CCR5) and
chemokine receptor 2 (CCR2) have been the focus of many
recent HIV-1 transmission and disease progression studies [4].
Chemokine receptor 5 (CCR5) is an HIV co-receptor utilized
by macrophage-tropic, or R5 strains of HIV-1 [5,6,7,8,9].
Homozygosity for a 32 base pair deletion (D32) in the open
reading frame (ORF) has been shown to confer almost complete
resistance to infection by R5 strains in adults [10,11,12,13,14].
This mutation has also been shown to be associated with reduced
expression of CCR5 [15]. Similarly, several CCR5 promoter
SNPs, principally -2459ARG and -2135CRT have been
associated with decreased transmission or disease progression
outcomes [16,17,18,19,20] as well as decreased infection and
susceptibility to infection in vitro [21,22]. A valine to isoleucine
substitution at codon 64 in the CCR2b gene, in linkage
disequilibrium with regions of the CCR5 promoter [23], is
associated with delayed disease progression in some, though not all
studies [23,24,25,26,27,28].
Because the various mutations in CCR2 and CCR5 are in
linkage disequilibrium, human haplotypes A-E, F*1, F*2, G*1, and
G*2 have been defined [29] (Figure 1).
Only a handful of studies have looked at CCR5 haplotype and
susceptibility to MTCT. Haplotype D homozygosity was associ-
ated with increased susceptibility to MTCT [18] as was both
haplotype E homozyogosity and heterozygosity [30]. A more
recent study found a protective effect against MTCT of
homozygosity for the G2 haplotype (D32) but only among children
of mothers with lower viral loads [31]. Thus, CCR5 haplotypes
appear to affect susceptibility to MTCT in a complex manner.
Here we studied a cohort of HIV positive women in Malawi to
determine whether individual CCR2/CCR5 haplotypes are associ-
ated with perinatal transmission of HIV-1. Although mothers
received nevirapine prior to delivery, approximately 20% of infants
became HIV infected [32]. We further investigated whether there
was an interaction between maternal viral load and polymorphisms
in determining a child’s relative risk of HIV acquisition.
METHODS
Data Collection
We conducted ancillary data analysis of a larger completed cohort
study described by Mwapasa et al, 2004 [33]. The original cohort
study was recruited from December 2000 to June 2002 at Queen
Elizabeth Central Hospital, Blanytre, Malawi. The estimated
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of whom lived in urban or periurban areas [33]. Study eligibility
was determined among pregnant women attending the antenatal
ward, after completing medical and obstetric assessment. Women
in active labor, living outside of Blantyre, less than 15 years of age,
with hypertension, or with altered consciousness were excluded.
Consenting HIV positive women received nevirapine prior to
delivery as well as post-HIV test counseling. Malaria infected
women were treated with sulfadoxine pyrimethamine or oral
quinine [33]. Infants of HIV-infected mothers received a single
dose of nevirapine at birth. Infant whole blood for HIV testing and
genotyping was collected at birth and at follow-up visits scheduled
6 and 12 weeks after delivery.
Laboratory Methods
Maternal HIV status was established by two concordant HIV
rapid tests (DetermineH, Abbott Laboratories, Abbott Park, IL,
USA, and SerocardH, Trinity BioTech, Dublin, Ireland). Infant
and maternal DNA was extracted from whole blood using the
QiAMP DNA Extraction Kit (Qiagen, Helden, Germany). Infant
HIV status at birth, 6 and 12 weeks was determined by real time
PCR [33]. Maternal HIV-1 RNA concentration measurements
were performed using the Roche Amplicor HIV-1 MonitorH Test,
version 1.5 (Roche Diagnostics, Branchburg, NJ). CD4 count was
determined by FACSCount (BD, San Jose, CA).
Detection of the CCR5 ORF D32 by analysis of amplified
fragment length polymorphisms was performed as previously
described [34]. Infant genotype at CCR2-64V/I and CCR5
promoter SNPs –2733A/G, -2554G/T, -2459A/G, -2135C/T,
-2132C/T, -2086A/G, -1835C/T was determined using a multi-
plex ligase detection reaction (LDR) based method with flow
cytometric technology [35]. Briefly, a 1,118 base pair fragment of
theCCR5promotercontainingtheseven promoter SNPsand a 327
base pair fragment in the CCR2 ORF were PCR-amplified. The
amplicon was then probed with two primers, an upstream allele
specific primer with a unique 24 nucleotide FlexMAP
TMTAG
sequence extension (LuminexH Corporation, Austin, TX) and
a downstream 59 phosphorylated/39 biotinylated conserved se-
quence primer. Following allele specific hybridization, the primers
were ligated. Ligation products were hybridized with fluorescent
bead-labelled anti-TAG probes, and the 39 biotin group labeled
with phycoerythrin (PE). Mean fluorescence intensity of the allele-
specific LDR:bead-labelled anti-TAG hybrid complexes was read
on a BioPlex array reader (Bio-Rad Laboratories, Hercules, CA)
into allele specific channels and used to determine genotypes (Bruse
et al in preparation).
The original cohort study was approved by the Malawi College
of Medicine Research and Ethics Committee and by the review
boards at the University of Michigan and the University of North
Carolina at Chapel Hill [33].
Figure 1. CCR2/CCR5 Haplotypes and abridged phylogenetic tree. Haplotypes were constructed based on the evolution of linked CCR2 and CCR5
mutations, including a valine to isoleucine substitution at codon 64 in the CCR2b gene (CCR2-64I), CCR5 mutations -2733ARG, -2554 GRT, -
2459ARG, -2135CRT, -2132CRT, -2086ARG, -1835CRT, and the delta-32 deletion in the open reading frame of CCR5 (CCR5-ORF).
doi:10.1371/journal.pone.0000838.g001
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CCR2/CCR5 SNPs were tested for Hardy-Weinberg Equilibrium
and Fisher’s Exact Test was used to estimate pair-wise associations
between MTCT and mutations or haplotypes, as well as the
association between MTCT and maternal CD4 count, maternal
viral load, maternal age, peripheral malaria parasite density, and
mode of delivery (vaginal or caesarian).
Log-linear regression was performed to determine the associ-
ation between each SNP and haplotype with MTCT. Due to the
rarity of some SNPs, 3 category genotypes (heterozygotes and
homozygous variant genotypes compared separately to the
homozygous wild type referent genotype) as well as the
presence/absence of the variant allele (hetero- and homozygous
variants combined as one group and compared to the referent)
were examined. Regression models were adjusted for all covariates
used in the imputation of log MVL. Adjustment for multiple
comparisons was made using the Bonferroni correction. Because
log MVL is a strong determinant of MTCT, effect measure
modification by MVL was examined by comparing results at
below and above the median value of log MVL (4.57).
The Likelihood Ratio Test (LRT) was used to test for
homogeneity of the associations between MTCT and SNP/
haplotype, across MVL categories.
These statistical analyses were performed in SAS version 9.1.3
(SAS, Cary, NC).
Three MTCT outcomes were examined: infants infected via
intrauterine transmission (IU), identified by a positive HIV PCR
result at birth; infants infected via intrapartum transmission (IP),
identified by first positive PCR result at six weeks after birth; and
infants infected via peripartum transmission (PP), identified at
week 12 of follow-up. A cumulative HIV transmission variable was
created to represent HIV infection at any follow-up time in the
study. To assess the consistency of our findings, sensitivity analyses
were performed by modeling the outcomes IU, IP, PP, and
cumulative transmission, in four separate models.
As the study progressed, it became too expensive to continue to
determine maternal HIV viral load for each mother ($40/person),
resulting in incomplete data for the last 22% of women to enroll in
the study. To address this issue, we investigated multiple
imputation for the missing maternal viral loads, using Markov
Chain Monte Carlo simulation [36,37,38]. To meet assumptions
of normality for imputation models, MVL was log-transformed.
Maternal CD4 count was found to be the only variable predictive
of the missingness of MVL and of MVL values; thus, it was the
only variable used in the imputation models. Of the genotyped
individuals, subjects missing data on both log MVL and maternal
CD4 count were excluded (2%), giving a total analysis sample size
of 529. Imputation models were performed in STATA version 9
use ICE and MICOMBINE commands.
RESULTS
Demographics
552 infants of HIV positive women provided a blood sample at
birth. 381 infants were captured at 6 weeks (69%) and 335 infants
were captured at 12 weeks (61%). A total of 101 became HIV
positive over the follow-up period (Table 1). Log transformed HIV
viral load was available for 402 mothers (mean=4.57, SD=0.72)
and after imputation, an additional 127 values were obtained
(overall mean=4.67, SD=0.66).
Allelic Frequencies of Haplotypes and SNPs
Amongalleligible birthsforthe study,the most commonhaplotypes
were HHA, HHD, HHE, and HHF2, with allelic frequencies of
0.44, 0.34, 0.29 and 0.34, respectively. A lower frequency of
haplotypes HHB (0.04) and HHF1 (0.09) was observed and HHG2
(bearing the D32 mutation) was absent (Figure 2). Allele frequencies
for CCR2/CCR5 SNPs are summarized in Figure 3.
Because of the rarity of some SNPs, the homozygous mutant
genotypes and heterozygotes were combined into one category
referred to as ‘‘carriers’’ of the mutation of interest, which was
compared to non-carriers of the mutation in regression models
(Table 2).
CCR5 polymorphism and MTCT
In bivariate analyses, only HHB appeared to increase the risk of
MTCT (RR=1.96, 95% CI=1.05, 3.66). This relationship was
not statistically significant after adjusting for multiple comparisons
(p=0.24). No other statistically significant associations between
individual haplotypes and MTCT were observed, although the
direction of haplotype associations was consistent with previous
reports [18,30] (Table 2). No association between CCR2-64I and
MTCT was observed, with an RR of approximately 1.0. A
protective effect was observed for CCR5 -2733G, -2459G,
-2135T, -2086G, and -1835T, and an increase in the risk of
MTCT was observed for CCR5 -2554T and -2132T, which are
consistent in direction with previous reports, but the associations
were not statistically significant (Table 2).
Effect of CCR5 polymorphisms on MTCT at different
MVL strata
In order to investigate whether MVL may be an effect measure
modifier similar tothatdescribed inOmetto et al.[31],we examined
whether the associations between SNPs and MTCT were homo-
geneous, after stratifying at the median value of log MVL (4.57,
which corresponds to a viral load of 37,000 copies/mL). Stratifica-
tion revealed that associations between CCR5 -2459G, CCR5
-2135T and MTCT were not homogeneous across MVL strata
(Table 3). This was confirmed by the likelihood ratio Chi-Square
(1 df) which was 3.83 for CCR5-2459G (p=0.05) and 3.60 for
CCR5-2135T (p=0.05). Thus, both SNPs appear to be protective
against MTCT at low MVL, but not high MVL (Table 4, Figure 4).
DISCUSSION
CCR5 plays a major role in host susceptibility to HIV-1 infection
[10,34,39]. In Blantyre, Malawi, among mothers with low viral
loads, this study found a reduction in the risk of MTCT in babies
bearing specific CCR5 variants. Reductions in the risk of MTCT
were found for two linked CCR5 mutations, CCR5 -2459G and
-2135T at low maternal viral loads.
Table 1. Frequency and HIV status of infants captured
through follow-up
......................................................................
Status N (%) At Birth 6 weeks* 12 weeks Cumulative{
HIV negative 501 (90.8) 340 (89.2) 285 (85.1) 451 (81.7)
HIV positive 51 (9.2) 41 (10.8) 50 (14.9) 101 (18.3)
Total captured 552 381 335 552
Missing 0 172 218 0
*HIV status at 6 weeks and at 12 weeks includes incident and prevalent cases of
HIV. Infants who missed week 6 and returned at week 12 or infants present at
week 6 but lost at week 12 were included in the summary.
{Cumulative follow-up includes all infants who were ever HIV positive,
regardless of loss to follow-up at one or more of the follow-up periods.
doi:10.1371/journal.pone.0000838.t001
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PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e838Figure 3. Haplotype Frequencies. Infant haplotype frequencies were calculated for all eligible births.
doi:10.1371/journal.pone.0000838.g003
Figure 2. Genotype Frequencies. Infant genotype frequencies were calculated for all eligible births. Wild type and variant alleles correspond to the
evolutionary history outlined in Figure 1.
doi:10.1371/journal.pone.0000838.g002
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e838The frequencies of CCR5 variants observed in our study are
similar to those reported in MTCT studies of African-American
populations, in particular the absence of the D32 mutation, the
very low frequency of HHB, and the relatively higher minor allele
frequency of CCR5 -2459G, -2135T, and -2132T [18,27].
Carriage of CCR5 -2459G mutation has been associated with
reduced density of CCR5 on CD14+ monocytes and lower levels
of R5 HIV propagation when compared to CCR5 -2459A
[21,40]. Thus, as with the D32 mutation, reduced expression is
correlated with protection against MTCT. The functional
significance of -2459G is a key characteristic of this SNP in
comparison to the other SNPs included in the haplotypes. Linkage
disequilibrium between -2459G and -2135T may explain the
similar findings for the two SNPs.
Our findings are somewhat different from 3 previous studies on
MTCT. While we did not find a significant association between
haplotype HHD homozygosity (bearing -2132T) and MTCT [18],
like Kostrikis et al. we found a non-significant association suggesting
that HHD was associated with increased risk of MTCT [18]. We
did not observe an effect of HHE carriage or homozygosity on
MTCT as seen in Argentinean children [30]. In contrast to John et
al. who did not observe any influence of CCR5 gene polymorphism
on MTCT in a Kenyan cohort, we observed a specific effect of
reduced MTCT in association with CCR5 promoter polymorph-
isms characterized by reduced gene expression [41].
There are four explanations for these discordant results. First,
our study was the only one to account for effect measure
modification by MVL. Second, our study was the only one to be
conducted in mother-infant pairs treated with nevirapine. Third,
all four studies were done in different populations where
contributions from other genetic and environmental cofactors
could occur. Finally, all of the studies comprise relatively small
numbers and conduct multiple comparisons, and could be
underpowered to find important associations.
All women and their babies received nevirapine which would
have reduced HIV inoculum size. Thus, nevirapine would likely
cause an underestimate of the effect seen in the absence of
treatment. There are many other determinants of transmission
including obstetric factors and mother-to-child microtransfusion
[42] that were not analyzed in our study but which should also
have affected our findings in a non-differential manner.
Nearly all (98% at 6 weeks, 96% at 12 weeks) women in our
study breast-fed. However, only 80% exclusively breast-fed at
6 weeks and only 46% exclusively breast-fed at 12 weeks.
Exclusive breastfeeding at either 6 or 12 weeks was not associated
with the main exposures (CCR5-2459G/-2135T) or the main
outcome (MTCT) of interest (Pearson Chi-square p-values.0.05);
thus was not viewed to be a potential confounder in the analysis.
To address the loss to follow-up in our study, we conducted
sensitivity analyses investigating the association between SNP and
MTCT at different times of follow-up in the study. Our results
showed that the effects of CCR5-2459G and -2135T are consistent
across follow-up (Table 5).
To address the fact that we were missing 22% of MVL data,
we conducted multiple imputation of MVL. Because only
CD4count was used in the imputation models, this was actually
Table 2. Association between Haplotype/SNP and MTCT
......................................................................
Haplotype/
SNP
Carrier
Status*
All Eligible
Births N (%)
MTCT Births
N (%) RR (95% CI){
A 22 308 (56.3) 54 (53.5) 1.12 (0.78, 1.59)
++/+2 239 (43.7) 47 (46.5)
B 22 526 (96.2) 94 (93.1) 1.96 (1.05, 3.66)
++/+2 21 (3.8) 7 (6.9)
C 22 441 (80.6) 86 (85.2) 0.72 (0.43, 1.20)
++/+2 106 (19.4) 15 (14.8)
D 22 363 (66.4) 62 (61.4) 1.24 (0.86, 1.77)
++/+2 184 (33.6) 39 (38.6)
E 22 387 (70.8) 72 (71.3) 0.97 (0.66, 1.43)
++/+2 160 (29.2) 29 (28.7)
F1 22 500 (91.4) 96 (95.1) 0.55 (0.24, 1.30)
++/+2 47 (8.6) 5 (4.9)
F2 22 362 (66.2) 68 (67.3) 0.95 (0.66, 1.39)
++/+2 185 (33.8) 33 (32.7)
G1 22 488 (89.2) 93 (92.1) 0.71 (0.36, 1.39)
++/+2 59 (10.8) 8 (7.9)
CCR2-64VRI 22 366 (66.2) 67 (66.3) 1.00 (0.69, 1.45)
++/+2 187 (33.8) 34 (33.7)
CCR5-2733ARG 22 488 (89.0) 93 (92.1) 0.70 (0.36, 1.36)
++/+2 60 (11.0) 8 (7.9)
CCR5-2554GRT 22 255 (46.5) 43 (42.6) 1.18 (0.82, 1.68)
++/+2 293 (53.5) 58 (57.4)
CCR5-2459ARG 22 160 (29.2) 35 (34.7) 0.78 (0.54, 1.12)
++/+2 388 (70.8) 66 (65.3)
CCR5-2135CRT 22 161 (29.3) 35 (34.7) 0.78 (0.54, 1.13)
++/+2 388 (70.7) 66 (65.3)
CCR5-2132CRT 22 362 (65.9) 61 (60.4) 1.27 (0.89, 1.81)
++/+2 187 (34.1) 40 (39.6)
CCR5-2086ARG 22 444 (80.7) 86 (85.1) 0.73 (0.44, 1.21)
++/+2 106 (19.3) 15 (14.9)
CCR5-1835CRT 22 325 (59.1) 64 (63.4) 0.84 (0.58, 1.21)
++/+2 225 (40.9) 37 (36.6)
*Non carriers of the haplotype or SNP were denoted as 22and carriers as
++/+2.
{The risk ratio (RR) was calculated from log linear regression, where non carriers
(22 ) were the referent. Maternal CD4 count, maternal age, and mode of
delivery were not significantly associated with the SNPs/haplotypes or MTCT.
Maternal viral load was significantly associated with MTCT but was not
associated with SNPs or haplotypes. Therefore, these covariates were not
included as confounders in the regression models.
doi:10.1371/journal.pone.0000838.t002
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Table 3. Likelihood Ratio Test (LRT) of Homogeneity* of the
association across MVL categories
......................................................................
SNP LRT p value
CCR2-64VRI 0.38 0.54
CCR5-2733ARG 0.71 0.40
CCR5-2554GRT 0.049 0.83
CCR5-2459ARG 3.83 0.05
CCR5-2135CRT 3.60 0.05
CCR5-2132CRT 0.001 0.97
CCR5-2086ARG 2.02 0.15
CCR5-1835CRT 0.53 0.47
*The LRT is the likelihood ratio Chi-Square with 1 degree of freedom, calculated
as the deviance of the full model minus the deviance of the reduced model,
where the models differed by inclusion of the interaction term.
doi:10.1371/journal.pone.0000838.t003
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..................................................................................................................................................
All Eligible Births N (%) MTCT Births N (%) RR (95% CI)*
Low MVL, CCR5 -2459G - - 77 (28.4) 16 (44.4) 1.0 (–)
Low MVL, CCR5 -2459G ++/+2 194 (71.6) 20 (55.6) 0.50 (0.27, 0.91)
High MVL, CCR5 -2459G - - 80 (29.4) 18 (28.1) 1.08 (0.60, 1.97)
High MVL, CCR5 -2459G ++/+2 192 (70.6) 46 (71.9) 1.16 (0.70, 1.92)
Low MVL, CCR5 -2135T - - 78 (28.8) 16 (44.4) 1.0 (–)
Low MVL, CCR5 -2135T ++/+2 193 (71.2) 20 (55.6) 0.51 (0.28, 0.92)
High MVL, CCR5 -2135T - - 80 (29.3) 18 (28.1) 1.10 (0.60, 1.99)
High MVL, CCR5 -2135T ++/+2 193 (70.7) 46 (71.9) 1.17 (0.71, 1.93)
*Non carriers of the SNP were denoted as 22and carriers as ++/+2.
{The risk ratio (RR) was calculated from log linear regression, where non carriers (22 ) were the referent.
doi:10.1371/journal.pone.0000838.t004
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Low MVL (<70,000)
CCR5-2459G/-2135T
High MVL (≥70,000)
Protection from MTCT 
    (RR~0.50, p=0.05)
      No effect 
(RR~1.16, p>0.05)
Figure 4. Effect Measure Modification by MVL. Carriers of CCR5 -2459G and -2135T with low MVL were protected from MTCT, whereas carriers of -
2459G and -2135T with high MVL demonstrated no change in susceptibility to MTCT.
doi:10.1371/journal.pone.0000838.g004
Table 5. Sensitivity analyses for SNP association with MTCT at different time points of follow-up
..................................................................................................................................................
SNP Model Birth RR (95% CI){ 6 weeks RR (95% CI) 12 weeks RR (95% CI) Cumulative RR (95% CI)
CCR5-2459ARG Overall 0.76 (0.44, 1.31) 0.93 (0.61, 1.44) 0.70 (0.47, 1.04) 1.00 (0.69, 1.45)
Low MVL 0.14 (0.04, 0.51) 0.38 (0.14, 1.00) 0.29 (0.11, 0.80) 0.70 (0.36, 1.36)
High MVL 1.38 (0.61, 3.10) 1.45 (0.78, 2.73) 1.03 (0.60, 1.80) 1.18 (0.82, 1.68)
CCR5-2135CRT Overall 0.76 (0.45, 1.32) 0.94 (0.61, 1.45) 0.70 (0.47, 1.05) 0.78 (0.54, 1.12)
Low MVL 0.14 (0.03, 0.52) 0.39 (0.15, 1.04) 0.30 (0.11, 0.83) 0.78 (0.54, 1.13)
High MVL 1.38 (0.61, 3.10) 1.46 (0.78, 2.73) 1.03 (0.60, 1.80) 1.27 (0.89, 1.81)
{The risk ratio (RR) was calculated from log linear regression, where non carriers (22 ) were the referent.
doi:10.1371/journal.pone.0000838.t005
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PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e838single imputation. This approach was viewed to be more accurate
than including variables that have no biological or statistical
significance for predicting MVL. Our imputation results show
that CCR5-2459G and -2135T are consistently associated with
MTCT both overall and after dichotomizing by MVL (Table 6).
Although a complete dataset is preferable, the missing data in our
study did not appear to be problematic for accurate interpreta-
tion of results.
The generalizability and replicability of our study may be
limited because the median value of log MVL (4.57) was used
to create the dichotomous variable. We could have used a value
of 4, which corresponds to a viral load of 10,000 copies/mL,
a more commonly used value in the literature. However, our
cut point was determined as a key component to a priori set
hypotheses.
Because log-linear regression models using imputed data are
considered to be experimental in STATA (version 9), we presented
odds ratios from logistic regression models to estimate risk ratios.
This may have biased our results away from the null, as odds ratios
from logistic regression generally overestimate the relative risks
from log-linear regression. However, we compared the results of
the experimental log-linear and logistic imputation models and
found similar results (data not shown).
In conclusion, this study characterized the role of infant CCR5
polymorphisms in susceptibility to MTCT in nevirapine-treated
African mother-infant pairs. Our results suggest a protective
effect of CCR5 -2459G and -2135T among infants of mothers
with low maternal viral load, which might be due to a reduction
in the expression of the CCR5 receptor. The influence of MVL
on this effect suggests that there may be a threshold in the ratio
of virus to receptor above which changes in the receptor
concentration have no effect on viral infectivity. Although our
study was not of heterosexual transmission, it may have
implications for microbicides designed to block access to CCR5
[43]. If a threshold exists for receptor access by virus, there will
also be a threshold for blocking receptor access by virus.
Ensuring that a CCR5-blocking microbicide is present at
a concentration that will not be overwhelmed by viral load is
critical. These findings are also applicable to antiretroviral drugs
such as CCR5 inhibitors [44] and chemoprophylaxis in high risk
populations, where delivery mechanisms differ from those of
vaginal microbicides. Continuing studies on the genetics of
MTCT will provide better insight into the pathophysiology and
prevention of HIV-1 MTCT with potential applications to other
modes of transmission.
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